| |
INTENDED AUDIENCE
Retina specialists and ophthalmologists
LEARNING OBJECTIVES
Upon completion of this CME activity, the participant should be able to:
- Explain how anti-VEGF therapy works and its duration of effect.
- Discuss techniques for using anti-VEGF therapy preoperatively.
- Debate the use of anti-VEGF agents as an adjunctive therapy for diabetic retinopathy and neovascular glaucoma.
ACCREDITATION AND DESIGNATION STATEMENTS
 Rush University Medical Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Rush University Medical Center designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Release Date: April 2009. The opinions or views expressed in this educational program are those of the participants and do not necessarily reflect the opinions or recommendations of Alcon Laboratories or Rush University Medical Center. The faculty may have included discussion on unlabeled uses of a commercial product or an investigational use of a product not yet approved for this purpose. Please consult the full prescribing information before using any medication mentioned in this educational program. This program has been produced in compliance with all ACCME Essential Areas and Elements and Accreditation Policies.
Expiration Date: April 30, 2010.
RUSH DISCLOSURE POLICY
It is the policy of the Rush University Medical Center Office of Continuing Medical Education to ensure that its CME activities are independent, free of commercial bias and beyond the control of persons or organizations with an economic interest in influencing the content of CME. Everyone who is in a position to control the content of an education activity must disclose all relevant financial relationships with any commercial interest (including but not limited to pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the presentation topic) within the preceding 12 months. If there are relationships that create a conflict of interest, these must be resolved by the CME Course Director in consultation with the Office of Continuing Medical Education prior to the participation of the faculty member in the development or presentation of course content.
 
|
 |
CME COURSE DIRECTOR
Kirk H. Packo, MD
Director, Department of Ophthalmology Rush University Medical Center, Chicago, Illinois
FACULTY
Bob Avery, MD
Faculty Staff Surgeon
California Retina Consultants and Research Foundation
Santa Barbara, California
DISCLOSURES
Kirk H. Packo, MD
Grant/Research/Support: Alcon Laboratories, Inc.
Consultant: None
Speakers' Bureau: None
Stock Shareholder: None
Robert Avery, MD
Grant/Research/Support: Genentech, Inc., Novartis
Consultant: Alcon Laboratories, Inc., Genentech, Inc., Novartis
Speakers' Bureau: Alcon Laboratories, Inc., Genentech, Inc.
Stock Shareholder: Alcon Laboratories, Inc., Novartis
|
|
